IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
Go back to IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late| (NASDAQ: IDYA) | Delayed: 34.23 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.23 | 52 Week High | $ | |||
| Open | $34.23 | 52 Week Low | $ | |||
| Day High | $34.23 | P/E | N/A | |||
| Day Low | $34.23 | EPS | $ | |||
| Volume | 233 | |||||
